Nkarta
Develops NKX019-led CAR NK therapies for B-cell autoimmune diseases.
Something off on this page? Send us feedback.
Profile
Develops pre-commercial, donor-derived CAR NK cell therapies for autoimmune disease, with NKX019 as the lead program. The business has one reportable segment, no approved products or product-sales revenue, and depends on clinical data, enrollment, manufacturing execution, regulatory approval, capital access, and competition from cell-therapy and immunology approaches.
Develops engineered natural killer cell therapies from healthy-donor cells, with NKX019 as the current lead program. The platform uses CD19-directed CAR NK cells and cryopreserved, off-the-shelf manufacturing for B-cell autoimmune diseases.
Clinical work centers on Ntrust-1 and Ntrust-2, plus investigator-sponsored NKX019 studies in systemic lupus erythematosus and myasthenia gravis. Earlier oncology studies for NKX019 and NKX101 closed enrollment and were deprioritized.
Operates as a pre-commercial biotech from South San Francisco with one reportable segment and no approved products or product-sales revenue. The business depends on patient enrollment, clinical data, cell-therapy manufacturing, regulatory approval, capital access, and competition from other cell-therapy and immunology approaches.
Company facts
Key statistics
Year to date +47.6% · Average volume (30d) 586.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | Cowen & Co. | Initiate | Buy | ||
| May 18, 2026 | Evercore ISI | Target | $9 | ||
| May 15, 2025 | William Blair | Downgrade | Outperform | Market Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.36 | −$0.54 | −49.9% | — | — | — | +2.58% |
| Aug 10, 2026Q2 FY26 | −$0.36 | −$0.54 | −49.9% | — | — | — | −5.28% |
| May 12, 2026Q1 FY26 | −$0.39 | −$0.37 | +5.1% | — | — | — | −6.71% |
| Mar 25, 2026Q4 FY25 | −$0.32 | −$0.37 | −15.6% | — | — | — | +0.47% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$2.3M | $0 | |
| Operating income | −$36.6M | −$27.2M | −$27.3M | −$31.0M | −$30.9M | −$43.1M | |
| Net income | −$32.0M | −$23.0M | −$21.7M | −$27.4M | −$27.8M | −$40.4M | |
| Diluted EPS | −$0.43 | −$0.31 | −$0.29 | −$0.37 | −$0.37 | −$0.54 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $182.8M · Total debt $73.5M · Total assets $337.6M · Shareholders' equity $247.7M
Dividends
No dividends on record.
Ownership
Shares outstanding 71.55M · Float 54.28M · 75.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10.81M | 15.10% | 13F | May 15, 2026 |
| BlackRock, Inc. | 4.51M | 6.30% | 13F | May 13, 2026 |
| Nea Management Company, LLC | 3.57M | 4.99% | 13F | May 15, 2026 |
| Samsara Biocapital, LLC | 3.51M | 4.90% | 13F | May 15, 2026 |
| Sr One Capital Management, LP | 3.33M | 4.66% | 13F | May 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 18, 2026 | Paul J. Hastings | director, officer: Chief Executive Officer | −1,776 | $2.71 |
| Jan 15, 2026 | Nadir Mahmood | officer: President | −5,649 | $2.07 |
| Jan 15, 2026 | Paul J. Hastings | director, officer: Chief Executive Officer | −26,046 | $2.07 |
Peers
- Kyverna Therapeutics
Autologous CD19 CAR-T immune-reset peer
- Cabaletta Bio
CD19 CAR-T RESET trials across core autoimmune indications
- Bristol-Myers Squibb
Scaled CD19 CAR-T autoimmune franchise with Phase 2 reach
- Fate
Off-the-shelf iPSC CD19 CAR-T for autoimmune disease
- Sana Biotechnology
Hypoimmune allogeneic CD19 CAR-T in lupus and AAV
- CRISPR Therapeutics
Allogeneic CRISPR-edited CD19 CAR-T in autoimmune trials
- Allogene Therapeutics
Allogeneic CD19/CD70 CAR-T for rheumatology basket
- Century Therapeutics
iPSC-derived CD19 CAR-iNK platform overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nkarta | $2.80 | +1.45% | $197.5M | — | — | — | — |
| Kyverna Therapeutics | $8.53 | +2.03% | $508.9M | — | — | — | — |
| Cabaletta Bio | $3.18 | +2.25% | $508.7M | — | — | — | — |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Fate | $2.43 | +0.60% | $283.2M | — | — | 43.6 | +9.2% |
| Sana Biotechnology | $3.95 | +0.51% | $1.09B | — | — | — | — |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Century Therapeutics | $2.03 | +0.25% | $175.3M | — | — | — | — |
| Median | 14.7 | 10.5 | 96.9 | +9.2% |